C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma
A year of cemiplimab after surgery and radiotherapy for high-risk cutaneous squamous cell carcinoma cut the risk of recurrence or death by more than two thirds, the first adjuvant therapy to work in this skin cancer.
Overview
Phase 3 placebo-controlled trial of 415 patients with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and postoperative radiotherapy (nodal disease with extracapsular extension, in-transit metastases, perineural invasion or recurrent tumours) randomised to cemiplimab or placebo for up to 48 weeks.
Disease-free survival at 24 months was 87.1 versus 64.1 percent (hazard ratio 0.32), with reductions in both locoregional and distant recurrence; grade 3 or higher adverse events were 23.9 versus 14.2 percent.
- 24-month disease-free survival 87.1 percent vs 64.1 percent; hazard ratio 0.32.
- Freedom from locoregional recurrence hazard ratio 0.20; from distant recurrence 0.35.
Adjuvant cemiplimab is a new standard for high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy, particularly in patients with extracapsular nodal extension.
- Overall survival data immature.
- Immunosuppressed and transplant patients, who bear much of the disease burden, were excluded.
Similar pages
not linked directly; found by shared links- Key paperNeoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
- Key paperPD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, New England Journal of Medicine.
- TrialStudy of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- TrialStudy Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- TrialAn Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.
- Key paperEMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum
- TrialEMPOWER-CSCC-1
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab.